329 related articles for article (PubMed ID: 33160076)
1. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
Predina JD; Haas AR; Martinez M; O'Brien S; Moon EK; Woodruff P; Stadanlick J; Corbett C; Frenzel-Sulyok L; Bryski MG; Eruslanov E; Deshpande C; Langer C; Aguilar LK; Guzik BW; Manzanera AG; Aguilar-Cordova E; Singhal S; Albelda SM
Mol Ther; 2021 Feb; 29(2):658-670. PubMed ID: 33160076
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
Kieran MW; Goumnerova L; Manley P; Chi SN; Marcus KJ; Manzanera AG; Polanco MLS; Guzik BW; Aguilar-Cordova E; Diaz-Montero CM; DiPatri AJ; Tomita T; Lulla R; Greenspan L; Aguilar LK; Goldman S
Neuro Oncol; 2019 Mar; 21(4):537-546. PubMed ID: 30883662
[TBL] [Abstract][Full Text] [Related]
3. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.
Aggarwal C; Haas AR; Metzger S; Aguilar LK; Aguilar-Cordova E; Manzanera AG; Gómez-Hernández G; Katz SI; Alley EW; Evans TL; Bauml JM; Cohen RB; Langer CJ; Albelda SM; Sterman DH
Mol Ther; 2018 May; 26(5):1198-1205. PubMed ID: 29550074
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
6. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Chiocca EA; Aguilar LK; Bell SD; Kaur B; Hardcastle J; Cavaliere R; McGregor J; Lo S; Ray-Chaudhuri A; Chakravarti A; Grecula J; Newton H; Harris KS; Grossman RG; Trask TW; Baskin DS; Monterroso C; Manzanera AG; Aguilar-Cordova E; New PZ
J Clin Oncol; 2011 Sep; 29(27):3611-9. PubMed ID: 21844505
[TBL] [Abstract][Full Text] [Related]
7. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Wheeler LA; Manzanera AG; Bell SD; Cavaliere R; McGregor JM; Grecula JC; Newton HB; Lo SS; Badie B; Portnow J; Teh BS; Trask TW; Baskin DS; New PZ; Aguilar LK; Aguilar-Cordova E; Chiocca EA
Neuro Oncol; 2016 Aug; 18(8):1137-45. PubMed ID: 26843484
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models.
Predina JD; Judy B; Aliperti LA; Fridlender ZG; Blouin A; Kapoor V; Laguna B; Nakagawa H; Rustgi AK; Aguilar L; Aguilar-Cordova E; Albelda SM; Singhal S
Cancer Gene Ther; 2011 Dec; 18(12):871-83. PubMed ID: 21869822
[TBL] [Abstract][Full Text] [Related]
10. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
11. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.
Rojas-Martínez A; Manzanera AG; Sukin SW; Esteban-María J; González-Guerrero JF; Gomez-Guerra L; Garza-Guajardo R; Flores-Gutiérrez JP; Elizondo Riojas G; Delgado-Enciso I; Ortiz-López R; Aguilar LK; Butler EB; Barrera-Saldaña HA; Aguilar-Cordova E
Cancer Gene Ther; 2013 Nov; 20(11):642-9. PubMed ID: 24052127
[TBL] [Abstract][Full Text] [Related]
12. [Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene transfer followed by ganiciclovir administration effectively inhibits growth of human small-cell lung cancer in a murine xenotransplant model].
Zhou JF; Chen G; Lu YP; Wang SX; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):68-70. PubMed ID: 15059319
[TBL] [Abstract][Full Text] [Related]
13. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
16. Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.
Predina JD; Kapoor V; Judy BF; Cheng G; Fridlender ZG; Albelda SM; Singhal S
J Hematol Oncol; 2012 Jun; 5():34. PubMed ID: 22742411
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
18. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.
Zhang JF; Wei F; Wang HP; Li HM; Qiu W; Ren PK; Chen XF; Huang Q
J Exp Clin Cancer Res; 2010 May; 29(1):52. PubMed ID: 20487549
[TBL] [Abstract][Full Text] [Related]
19. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant intratumoral immuno-gene therapy for non-small cell lung cancer.
Predina JD; Keating J; Venegas O; Nims S; Singhal S
Discov Med; 2016 Apr; 21(116):275-81. PubMed ID: 27232513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
